Deanna Zhu

ORCID: 0000-0003-1339-9375
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Mosquito-borne diseases and control
  • Viral Infections and Vectors
  • Insect symbiosis and bacterial influences
  • Malaria Research and Control
  • SARS-CoV-2 and COVID-19 Research
  • Toxoplasma gondii Research Studies
  • Viral Infections and Outbreaks Research
  • Cytomegalovirus and herpesvirus research
  • Animal Virus Infections Studies
  • Infection Control and Ventilation
  • Biosimilars and Bioanalytical Methods
  • Cell Image Analysis Techniques
  • SARS-CoV-2 detection and testing
  • COVID-19 and Mental Health
  • Dengue and Mosquito Control Research
  • Bacillus and Francisella bacterial research
  • COVID-19 epidemiological studies
  • COVID-19 Clinical Research Studies
  • Travel-related health issues
  • HIV Research and Treatment
  • Immunotherapy and Immune Responses
  • Fungal Infections and Studies
  • Herpesvirus Infections and Treatments
  • Infection Control in Healthcare
  • Burn Injury Management and Outcomes

University of North Carolina at Chapel Hill
2020-2023

Saint Louis University
2023

Max Planck Institute for Biology
2023

Fred Hutch Cancer Center
2023

UCLouvain Saint-Louis Brussels
2023

Abstract The four dengue virus serotypes co-circulate globally and cause significant human disease. Dengue vaccine development is challenging because some virus-specific antibodies are protective, while others implicated in enhanced viral replication more severe Current tetravalent vaccines contain live attenuated formulated to theoretically induce balanced protective immunity. Among the number of candidates clinical trials, only Dengvaxia licensed for use DENV seropositive individuals. To...

10.1038/s41467-023-36702-x article EN cc-by Nature Communications 2023-03-13

ABSTRACT The four dengue virus (DENV) serotypes cause several hundred million infections annually. Several live-attenuated tetravalent vaccines (LAVs) are at different stages of clinical testing and regulatory approval. A major hurdle faced by the two leading LAVs is uneven replication vaccine stimulating a dominant response to one serotype expense other three, potential for antibody (Ab)-enhanced, more severe wild-type (WT) DENV that fail replicate in vaccine. Protein subunit promising...

10.1128/jvi.00229-25 article EN cc-by Journal of Virology 2025-04-16

Few studies have described changes in SARS-CoV-2 antibody levels response to infection and vaccination at frequent intervals over extended follow-up periods. The purpose of this study was assess SARS-CoV-2-specific responses among a prospective cohort health care personnel 18 months with up 22 samples per person. Antibody live virus neutralization were measured before after mRNA-based results stratified by (1) status prior initial (2) any point during follow-up. We found that the first dose...

10.1093/ofid/ofae009 article EN cc-by Open Forum Infectious Diseases 2024-01-01

Abstract The effect of SARS-CoV-2 infection on response to mRNA-based vaccines is not well-described. We assessed longitudinal SARS-CoV-2-specific antibody responses pre- and post-vaccination among individuals with without prior infection. the first vaccine dose was almost two-fold higher in who were seropositive before vaccination compared those seronegative, suggesting that primes immune vaccine.

10.1101/2021.02.09.21251319 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2021-02-19

Background Health care personnel (HCP) are at high risk for exposure to the SARS-CoV-2 virus. While personal protective equipment (PPE) may mitigate this risk, prospective data collection on its use and other factors seroconversion in population is needed. Objective The primary objectives of study (1) determine incidence of, for, infection among HCP a tertiary medical center (2) actively monitor PPE use, interactions between participants via electronic sensors, secondary cases households,...

10.2196/25410 article EN cc-by JMIR Research Protocols 2021-03-18

ABSTRACT The DENV envelope (E) and pre-membrane (prM) glycoproteins are primary targets of serologic immunity after infection vaccination. Of these, serotype-specific (TS) antibodies typically target E domains, while serotype cross-reactive (CR) the prM protein conserved regions. To identify quantify E-domain TS neutralizing antibody responses in polyclonal sera, we developed a panel chimeric DENV4/2 viruses that incorporate DENV2 domain I, II, III (DENV4/2-EDI, EDII, EDIII) into DENV4...

10.1128/mbio.00818-23 article EN cc-by mBio 2023-10-06

Diagnosis of toxoplasmic encephalitis (TE) is challenging under the best clinical circumstances. The poor sensitivity quantitative polymerase chain reaction (qPCR) for Toxoplasma in blood and CSF limited availability molecular diagnostics imaging technology leaves clinicians resource-limited settings with few options other than empiric treatment. Here we describe proof concept a novel urine TE using Poly-N-Isopropylacrylamide nanoparticles dyed Reactive Blue-221 to concentrate antigens,...

10.1371/journal.pntd.0009199 article EN cc-by PLoS neglected tropical diseases 2021-03-02

A hallmark of dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which associated with deadly DENV secondary infection, complicates identification correlates protection, and negatively impacts safety efficacy vaccines. Antibody-dependent enhancement linked to antibodies targeting fusion loop (FL) motif envelope protein, completely conserved in mosquito-borne flaviviruses required viral entry fusion. In current study, we utilized saturation mutagenesis...

10.7554/elife.87555.3 article EN cc-by eLife 2023-09-19

The four-dengue virus (DENV) serotypes cause several hundred million infections annually. Several live-attenuated tetravalent dengue vaccines (LAVs) are at different stages of clinical testing and regulatory approval. A major hurdle faced by the two leading LAVs is uneven replication vaccine stimulating a dominant response to one serotype expense other three, potential for antibody (Ab) enhanced more severe wild type DENV that fail replicate in vaccine. Protein subunit promising alternative...

10.1101/2024.07.18.604114 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2024-07-18

A hallmark of dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which associated with deadly DENV secondary infection, complicates identification correlates protection, and negatively impacts safety efficacy vaccines. Antibody-dependent enhancement linked to antibodies targeting fusion loop (FL) motif envelope protein, completely conserved in mosquito-borne flaviviruses required viral entry fusion. In current study, we utilized saturation mutagenesis...

10.7554/elife.87555 article EN cc-by eLife 2023-07-12

Abstract Background Diagnosis of toxoplasmic encephalitis (TE) is challenging under the best clinical circumstances. The poor sensitivity quantitative polymerase chain reaction (qPCR) for Toxoplasma in blood and CSF limited availability molecular diagnostics imaging technology leaves clinicians resource-limited settings with few options other than empiric treatment. Methology/Principle Findings Here we describe proof concept a novel urine TE using Poly-N-isoproplyacrylamide nanoparticles...

10.1101/2020.07.31.20165951 preprint EN cc-by-nc medRxiv (Cold Spring Harbor Laboratory) 2020-07-31

<sec> <title>BACKGROUND</title> Health care personnel (HCP) are at high risk for exposure to the SARS-CoV-2 virus. While personal protective equipment (PPE) may mitigate this risk, prospective data collection on its use and other factors seroconversion in population is needed. </sec> <title>OBJECTIVE</title> The primary objectives of study (1) determine incidence of, for, infection among HCP a tertiary medical center (2) actively monitor PPE use, interactions between participants via...

10.2196/preprints.25410 preprint EN cc-by 2020-11-17

ABSTRACT A hallmark of Dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which associated with deadly DENV secondary infection, complicates identification correlates protection, and negatively impacts safety efficacy vaccines. ADE linked to antibodies targeting fusion loop (FL) motif envelope protein, completely conserved in mosquito-borne flaviviruses required viral entry fusion. In current study, we utilized saturation mutagenesis directed evolution...

10.1101/2023.03.22.533803 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2023-03-27

A hallmark of Dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which associated with deadly DENV secondary infection, complicates identification correlates protection, and negatively impacts safety efficacy vaccines. Antibody-dependent enhancement linked to antibodies targeting fusion loop (FL) motif envelope protein, completely conserved in mosquito-borne flaviviruses required viral entry fusion. In current study, we utilized saturation mutagenesis...

10.7554/elife.87555.1 preprint EN 2023-07-12

A hallmark of Dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which associated with deadly DENV secondary infection, complicates identification correlates protection, and negatively impacts safety efficacy vaccines. ADE linked to antibodies targeting fusion loop (FL) motif envelope protein, completely conserved in mosquito-borne flaviviruses required viral entry fusion. In current study, we utilized saturation mutagenesis directed evolution engineer a...

10.7554/elife.87555.2 preprint EN 2023-09-08

Abstract Background Neurological opportunistic infections cause significant morbidity and mortality in people with human immunodeficiency virus (HIV) but are difficult to diagnose. Methods One hundred forty HIV acute neurological symptoms from Iquitos, Peru, were evaluated for cerebral toxoplasmosis quantitative polymerase chain reaction (qPCR) of cerebrospinal fluid (CSF) cryptococcal meningitis antigen test (CrAg) serum or CSF. Differences between groups assessed standard statistical...

10.1093/ofid/ofad515 article EN cc-by Open Forum Infectious Diseases 2023-10-27
Coming Soon ...